ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ABVX vs JNJ // EV/EBITDA & P/E VALUATION

Abivax SA (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ABVX 1 — JNJ 10
▲ EV/EBITDA & P/E VALUATION LEADER: JNJ
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABVX VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ABVX JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% 25.50% -15.60 JNJ /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 21.0x 18.5x +2.50 JNJ /valuation <GO>
Free Cash Flow Yield 2.21% 2.97% -0.76 JNJ /fcf-yield <GO>
Operating Margin 13.90% 34.70% -20.80 JNJ /operating-margins <GO>
Net Profit Margin 10.90% 28.50% -17.60 JNJ /net-margins <GO>
Revenue Growth (YoY) 8.80% 6.00% +2.80 ABVX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 5.59 -1.85 JNJ /balance-sheet <GO>
Piotroski F-Score Quality 8/9 8/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.7 62.1 -17.40 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.05 1.08 -0.03 JNJ /macro-sensitivity <GO>
Forward P/E Multiple 30.5x 23.0x +7.50 JNJ /forward-pe <GO>
Enterprise Scale & Market Cap $7.77B $662.49B -$654.72B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ABVX REV JNJ REV ABVX GROSS % JNJ GROSS % ABVX FCF JNJ FCF
FY 2025 — $94.19B — 67.9% — $19.70B
FY 2024 — $88.82B — 69.1% — $19.84B
FY 2023 — $85.16B — — — $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABVX // BETA 1.05
JNJ // BETA 1.08